BRD2 and non-small cell lung carcinoma: In our study, we had demonstrated that dose-dependent NAT-F treatment induced ROS production and up-regulated p38 and JNK phosphorylation, and ERK1/2 phosphorylated level was significantly suppressed for NAT-F treatment in both NSCLC cells.